主页 > 医学动态 >
【drug-news】Vytorin门事件是否应扣除先灵保雅CEO的
Vytorin门事件是否应扣除先灵保雅CEO的奖金?
May 19, 2008, 9:43 am
Should Vytoringate Cost Fred Hassan His Bonus?
Posted by Sarah Rubenstein
Schering-Plough CEO Fred Hassan looked like quite the turnaround artist as he nursed the company back to health after it had been battered by generic competition for Claritin and regulatory problems.
Lately, though, things have taken a gloomy turn for Schering-Plough as cholesterol drugs Vytorin and Zetia — and the company’s stock price — have taken a beating. Take a look at the chart and you’ll see shares have fallen back to where they were about five years ago.
Does the mess mean Hassan should give back his bonus? Forbes makes a case that it should, arguing that Hassan received $13 million in cash that would have been endangered if the ill-fated Enhance study’s results had come out in November 2006 or March 2007, as many cardiologists had expected. Forbes points out the payouts were heavily dependent on strong sales of Vytorin that might not have come to be if doctors had known sooner that the trial wouldn’t turn out so well.
Schering-Plough took issue with the argument. For one, it denied the study could have been ready in 2006, when Hassan got $9 million of the cash bonuses. It also said Forbes didn’t take into account that the company might have conducted business differently last year if Vytorin were in trouble then, for instance cutting costs more aggressively or emphasizing other products.
It’s also tough to know exactly what would have happened to Vytorin’s sales if the study’s results had come out earlier. The Health Blog isn’t one to blame the media for Vytorin’s woes, but we wonder if the results would have gotten so much attention — and affected sales as acutely — if the long delay hadn’t caused so much suspicion in the first place.
网友评论
Comments
Report offensive comments to healthblog@wsj.com
Forbes is exactly right. From all indications study results were withheld costing consumers and governments millions of dollars for Vytorin.
Comment by Marusa - May 19, 2008 at 9:58 am
Are you guys so desperate to write something that you have to resort to woulda, coulda, shouda. The deal was made. He got paid, and to write that maybe he should return the pay, is ridiculous. You can bet it won’t happen.
In my opinion Schering-Plough has been unfairly criticised, or at least kept in the news too long. Please have your publication go on to something that might really help; check the Oil futures market. There is no shortage of oil. Just the lack of oversight and control. Let’s advocate doing away with the futures markets altogether, and let Schering-Plough heal itself.
Comment by Fred Hassan article - May 19, 2008 at 10:07 am
The ENHANCE study looked at a specific group of people with extremely high LDL’s who had been on other statins before Vytorin. They had very little artery thickening to begin with. The real matter is, the lower you can get your LDL, the less is your cardiovascular risk. Vytorin does a great job at lowering LDL.
Comment by Michael Brennan MD - May 19, 2008 at 10:29 am
They should only have studied the endpoint of does it reduce LDL better than other drugs! The person who chose the endpoints of reducing arterial thickening should be severely dealt with! Vytorin does a great job and I’m still taking it. They should have focused on the fact that it is still a safe drug and many doctors still use it for patients with a high LDL.
Comment by anonymous patient - May 19, 2008 at 10:49 am
Sarah, just to give your readers a full perspective on the Forbes.com story, I’m including here the comment that I posted earlier this morning on the Forbes site.
Susan Wolf
(Comment posted on Forbes.com)
The innuendo of this article on the character of our CEO is very unfair.
Fred Hassan has a distinguished track record as a CEO who is virtually synonymous with integrity. We see this in his actions every day.
Fred Hassan also has a proven track record as a CEO who has taken a series of some of the biggest challenges in the world of business and turned them around to the benefit of patients, shareowners and society.
Schering-Plough proved to be the toughest challenge of Fred’s career, and he and his management team succeeded against long odds in transforming our company — including important corporate governance and compliance actions to build business integrity into the DNA of the company and to align management incentives with the interests of shareholders.
When Fred joined us in 2003, when our company was in dire straits, he voluntarily gave up his bonus of up to $2 million. Since then, Fred has invested very large amounts of his own personal assets into Schering-Plough - first buying $4.6 million of Schering-Plough stock soon after he took over as CEO: then again buying another $2 million in company stock in April of this year.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-11-08 05:11
医学,生命科学网